atenolol has been researched along with oxazepam in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (25.00) | 18.7374 |
| 1990's | 4 (12.50) | 18.2507 |
| 2000's | 10 (31.25) | 29.6817 |
| 2010's | 9 (28.13) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Ghuloum, AM; Jain, AN; Sage, CR | 1 |
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Ertl, P; Rohde, B; Selzer, P | 1 |
| Artursson, P; Luthman, K; Norinder, U; Stenberg, P | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Caron, G; Ermondi, G | 1 |
| Carrupt, PA; Martel, S; Ottaviani, G | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ganeshpurkar, A; Gupta, SK; Gutti, G; Krishnamurthy, S; Kumar, D; Modi, G; Singh, SK | 1 |
| Rai, SN; Shankar, S; Sharma, P; Shrivastava, SK; Singh, SP; Srivastava, P; Srivastava, RK; Tripathi, PN | 1 |
| Sharma, P; Shrivastava, SK; Srivastava, P; Tripathi, PN | 1 |
| Jaiswal, S; Raja Ayyannan, S; Tiwari, V; Uniyal, A | 1 |
| Currie, D; Lewis, RV; McDevitt, DG; Nicholson, AN; Wright, NA | 2 |
| Currie, D; McDevitt, DG; Nicholson, AN; Wright, NA; Zetlein, MB | 3 |
| Gottlieb, LD; Horwitz, RI; Kraus, ML | 1 |
| McDevitt, DG | 1 |
| Gottlieb, LD | 1 |
| Harms, D; Nechvatal, D; Pachale, E | 2 |
1 review(s) available for atenolol and oxazepam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 trial(s) available for atenolol and oxazepam
| Article | Year |
|---|---|
Central effects of the angiotensin-converting enzyme inhibitor, captopril. I. Performance and subjective assessments of mood.
Topics: Adult; Affect; Atenolol; Blood Pressure; Captopril; Heart Rate; Humans; Hypertension; Male; Oxazepam; Psychomotor Performance | 1990 |
Central effects of the angiotensin-converting enzyme inhibitor, captopril. II. Electroencephalogram and body sway.
Topics: Atenolol; Captopril; Electroencephalography; Humans; Male; Oxazepam; Postural Balance | 1990 |
The efficacy of atenolol in the outpatient management of the alcohol withdrawal syndrome. Results of a randomized clinical trial.
Topics: Adult; Alcoholism; Atenolol; Double-Blind Method; Female; Humans; Male; Middle Aged; Oxazepam; Prognosis; Random Allocation; Substance Withdrawal Syndrome | 1989 |
Beta-blockers and psychometric performance: studies in normal volunteers.
Topics: Adrenergic beta-Antagonists; Atenolol; Diazepam; Dose-Response Relationship, Drug; Humans; Lipid Metabolism; Nadolol; Oxazepam; Propanolamines; Propranolol; Psychometrics; Psychomotor Performance; Random Allocation; Reaction Time; Reference Values; Solubility; Time Factors | 1985 |
The role of beta blockers in alcohol withdrawal syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Ethanol; Humans; Middle Aged; Oxazepam; Random Allocation; Substance Withdrawal Syndrome | 1988 |
Central effects of beta-adrenoceptor antagonists. I--Performance and subjective assessments of mood.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Attention; Double-Blind Method; Electroencephalography; Emotions; Flicker Fusion; Heart Rate; Humans; Male; Memory, Short-Term; Oxazepam; Propranolol; Psychomotor Performance; Random Allocation; Reaction Time | 1988 |
Central effects of beta-adrenoceptor antagonists. II--Electroencephalogram and body sway.
Topics: Adrenergic beta-Antagonists; Atenolol; Electroencephalography; Humans; Oxazepam; Postural Balance; Propranolol | 1988 |
[Vigilance and beta blockade. The influence of the beta blocker atenolol and other substances on the reaction time of the visual system].
Topics: Adrenergic beta-Antagonists; Adult; Amphetamines; Atenolol; Attention; Diazepam; Humans; Male; Oxazepam; Propanolamines; Reaction Time; Theophylline; Visual Perception | 1981 |
Influence of the beta-blocking atenolol and other medications on visual reaction time.
Topics: Adult; Amphetamines; Atenolol; Central Nervous System Stimulants; Diazepam; Drug Interactions; Ethanol; Humans; Male; Oxazepam; Propanolamines; Reaction Time; Theophylline; Time Factors; Vision, Ocular | 1981 |
Central effects of repeated administration of atenolol and captopril in healthy volunteers.
Topics: Adult; Atenolol; Attention; Blood Pressure; Captopril; Central Nervous System; Electroencephalography; Flicker Fusion; Heart Rate; Humans; Male; Memory, Short-Term; Mental Recall; Methyldopa; Oxazepam; Psychomotor Performance; Reaction Time | 1994 |
21 other study(ies) available for atenolol and oxazepam
| Article | Year |
|---|---|
Molecular hashkeys: a novel method for molecular characterization and its application for predicting important pharmaceutical properties of molecules.
Topics: Drug Design; Intestinal Absorption; Models, Molecular; Pharmaceutical Preparations; Structure-Activity Relationship | 1999 |
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
Topics: Biological Availability; Biological Transport; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Reproducibility of Results | 2000 |
Experimental and computational screening models for the prediction of intestinal drug absorption.
Topics: Biological Transport; Carbon Radioisotopes; Cell Line; Cell Membrane; Cell Membrane Permeability; Ciprofloxacin; Computational Biology; Drug Design; Foscarnet; Humans; Hydrogen Bonding; Intestinal Absorption; Intestinal Mucosa; Lactulose; Mannitol; Models, Biological; Raffinose; Surface Properties; Tritium; Verapamil | 2001 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
Topics: Humans; Membranes, Artificial; Models, Biological; Models, Molecular; Octanols; Permeability; Pharmaceutical Preparations; Skin Absorption; Water | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Diketopiperazines; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Matrix Metalloproteinase 2; Molecular Structure; Neuroprotective Agents; Structure-Activity Relationship | 2018 |
Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory.
Topics: Antioxidants; Benzoxazoles; Cholinesterase Inhibitors; Drug Design; Humans; Learning; Memory; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2019 |
Design, synthesis, and evaluation of novel N-(4-phenoxybenzyl)aniline derivatives targeting acetylcholinesterase, β-amyloid aggregation and oxidative stress to treat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Drug Design; Humans; Oxidative Stress | 2019 |
Synthesis and evaluation of dual fatty acid amide hydrolase-monoacylglycerol lipase inhibition and antinociceptive activities of 4-methylsulfonylaniline-derived semicarbazones.
Topics: Amidohydrolases; Analgesics; Enzyme Inhibitors; Humans; Molecular Docking Simulation; Monoacylglycerol Lipases; Neuralgia; Semicarbazones | 2022 |
Beta-blockers, mood and behaviour.
Topics: Adult; Affect; Atenolol; Humans; Male; Memory, Short-Term; Oxazepam; Propranolol; Psychomotor Performance | 1988 |